FDA Approves GSK’s RSV Vaccine for Older Adults
Wall Street Journal
GSK’s Arexvy respiratory syncytial virus vaccine has been approved by the U.S. Food and Drug Administration for people 60 years old and older.
https://www.wsj.com/articles/fda-approves-gsks-rsv-vaccine-for-older-adults-9c2c5